Aventis “Contingency Plans” For Allegra Include Outlicensing
This article was originally published in The Tan Sheet
Executive Summary
Aventis is considering outlicensing the antihistamine Allegra (fexofenadine) as a "contingency plan" in the event that the product loses its sole-source prescription-only statusYou may also be interested in...
NSAID, Antihistamine Use More Affected By Copay Raise Than Other Rxs – Study
Consumer spending on prescription non-steroidal anti-inflammatories and antihistamines decreased 45% and 44%, respectively, when insurance copays for the products doubled, according to a study published in the Journal of the American Medical Association May 19
NSAID, Antihistamine Use More Affected By Copay Raise Than Other Rxs – Study
Consumer spending on prescription non-steroidal anti-inflammatories and antihistamines decreased 45% and 44%, respectively, when insurance copays for the products doubled, according to a study published in the Journal of the American Medical Association May 19
NSAID, Antihistamine Use More Affected By Copay Raise Than Other Rxs – Study
Consumer spending on prescription non-steroidal anti-inflammatories and antihistamines decreased 45% and 44%, respectively, when insurance copays for the products doubled, according to a study published in the Journal of the American Medical Association May 19
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: